Literature DB >> 16905728

Bimodal virological response to antiretroviral therapy for HIV infection: an application using a mixture model with left censoring.

Xiuhong Li1, Haitao Chu, Joel E Gallant, Donald R Hoover, Wendy J Mack, Joan S Chmiel, Alvaro Muñoz.   

Abstract

STUDY
OBJECTIVE: To assess whether HIV RNA levels (log(10) scale) in highly active antiretroviral therapy (HAART) treated population have a bimodal distribution, suggesting optimal or suboptimal response to HAART.
METHODS: The study population from two ongoing cohort studies comprised 564 men (4785 person visits) and 1173 women (8675 person visits) with known dates of HAART initiation and with HIV RNA measurements before and after initiation. Values below detection limit of assays were treated in the analysis as left censored. Maximum likelihood methods were used to estimate parameters and to determine possible bimodality of HIV RNA distributions.
RESULTS: A two component mixture model fitted HIV RNA levels significantly better than did a single component distribution at different years from HAART initiation in both therapy experienced and therapy naive patients. In the fifth year after HAART initiation, 32% of men and 44% of women had HIV RNA in the higher component with medians of 5247 and 9253 copies/ml, respectively, suggesting suboptimal virological response to HAART, which was associated with poor adherence and lower frequency of CCR5 heterozygous genotype.
CONCLUSION: The bimodal distribution of HIV RNA persisted during the years after HAART initiation. The high occurrence of suboptimal virological response at the fifth year after HAART initiation underscore the needs for careful monitoring and patient education about the importance of treatment adherence. This data analysis overcomes limitations of measurement techniques of observations having values below detection limits and serves to characterise the dynamics of the virological response to therapies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16905728      PMCID: PMC2566033          DOI: 10.1136/jech.2005.044644

Source DB:  PubMed          Journal:  J Epidemiol Community Health        ISSN: 0143-005X            Impact factor:   3.710


  25 in total

1.  Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease.

Authors:  C Piketty; P Castiel; L Belec; D Batisse; A Si Mohamed; J Gilquin; G Gonzalez-Canali; D Jayle; M Karmochkine; L Weiss; J P Aboulker; M D Kazatchkine
Journal:  AIDS       Date:  1998-05-07       Impact factor: 4.177

2.  Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study.

Authors:  B Ledergerber; M Egger; M Opravil; A Telenti; B Hirschel; M Battegay; P Vernazza; P Sudre; M Flepp; H Furrer; P Francioli; R Weber
Journal:  Lancet       Date:  1999-03-13       Impact factor: 79.321

3.  Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories.

Authors:  B Yen-Lieberman; D Brambilla; B Jackson; J Bremer; R Coombs; M Cronin; S Herman; D Katzenstein; S Leung; H J Lin; P Palumbo; S Rasheed; J Todd; M Vahey; P Reichelderfer
Journal:  J Clin Microbiol       Date:  1996-11       Impact factor: 5.948

4.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

5.  The Women's Interagency HIV Study. WIHS Collaborative Study Group.

Authors:  S E Barkan; S L Melnick; S Preston-Martin; K Weber; L A Kalish; P Miotti; M Young; R Greenblatt; H Sacks; J Feldman
Journal:  Epidemiology       Date:  1998-03       Impact factor: 4.822

6.  Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users.

Authors:  Patrick M Tarwater; Joel E Gallant; John W Mellors; Mary E Gore; John P Phair; Roger Detels; Joseph B Margolick; Alvaro Muñoz
Journal:  AIDS       Date:  2004-12-03       Impact factor: 4.177

7.  Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons.

Authors:  F W Wit; R van Leeuwen; G J Weverling; S Jurriaans; K Nauta; R Steingrover; J Schuijtemaker; X Eyssen; D Fortuin; M Weeda; F de Wolf; P Reiss; S A Danner; J M Lange
Journal:  J Infect Dis       Date:  1999-04       Impact factor: 5.226

8.  Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators.

Authors:  R Detels; A Muñoz; G McFarlane; L A Kingsley; J B Margolick; J Giorgi; L K Schrager; J P Phair
Journal:  JAMA       Date:  1998-11-04       Impact factor: 56.272

9.  Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection.

Authors:  A d'Arminio Monforte; L Testa; F Adorni; E Chiesa; T Bini; G C Moscatelli; C Abeli; S Rusconi; S Sollima; C Balotta; M Musicco; M Galli; M Moroni
Journal:  AIDS       Date:  1998-09-10       Impact factor: 4.177

10.  The Multicenter AIDS Cohort Study: retention after 9 1/2 years.

Authors:  J Dudley; S Jin; D Hoover; S Metz; R Thackeray; J Chmiel
Journal:  Am J Epidemiol       Date:  1995-08-01       Impact factor: 4.897

View more
  4 in total

1.  The effect of HAART on HIV RNA trajectory among treatment-naïve men and women: a segmental Bernoulli/lognormal random effects model with left censoring.

Authors:  Haitao Chu; Stephen J Gange; Xiuhong Li; Donald R Hoover; Chenglong Liu; Joan S Chmiel; Lisa P Jacobson
Journal:  Epidemiology       Date:  2010-07       Impact factor: 4.822

2.  Improved estimation of the distribution of suppressed plasma HIV-1 RNA in men receiving effective antiretroviral therapy.

Authors:  Michael F Schneider; Joseph B Margolick; Lisa P Jacobson; Susheel Reddy; Otoniel Martinez-Maza; Alvaro Muñoz
Journal:  J Acquir Immune Defic Syndr       Date:  2012-04-01       Impact factor: 3.731

3.  CD4+ T-cell counts and plasma HIV-1 RNA levels beyond 5 years of highly active antiretroviral therapy.

Authors:  Xiuhong Li; Joseph B Margolick; Beth D Jamieson; Charles R Rinaldo; John P Phair; Lisa P Jacobson
Journal:  J Acquir Immune Defic Syndr       Date:  2011-08-15       Impact factor: 3.731

4.  Virologic response of adolescents living with perinatally acquired HIV receiving antiretroviral therapy in the period of early adolescence (10-14 years) in South Africa.

Authors:  Patience Nyakato; Michael Schomaker; Nosisa Sipambo; Karl-Günter Technau; Geoffrey Fatti; Helena Rabie; Frank Tanser; Brian Eley; Jonathan Euvrard; Robin Wood; Priscilla R Tsondai; Constantin T Yiannoutsos; Morna Cornell; Mary-Ann Davies
Journal:  AIDS       Date:  2021-05-01       Impact factor: 4.632

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.